Skip to content

Study · Not a test of the peptide alone · 2023

2 results

A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options.

Png D, Yeoh E, Tan C, Lim SC

Journal of investigative medicine high impact case reports1 Jan 2023Cited by 7 (Europe PMC)

PMID36644884 (opens in a new tab)PMCIDPMC9846294 (opens in a new tab)DOI10.1177/23247096221150631 (opens in a new tab)PepBankPUB-36644884
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In the younger sibling with Wolfram syndrome, treatment with liraglutide plus tauroursodeoxycholic acid was followed by lower insulin requirements.

    In plain wordsIn one person with Wolfram syndrome, liraglutide given with another drug was followed by lower insulin needs. The effect of liraglutide alone is unknown.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin requirement
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There was reduction in insulin requirements and improvement in glycemic control.
    1 context sentence
    Summary · context
    Treatment with liraglutide, a glucagon-like-peptide-1 receptor agonist, and tauroursodeoxycholic acid was started for the younger sibling, the proband.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In the younger sibling with Wolfram syndrome, glycemic control improved after treatment with liraglutide plus tauroursodeoxycholic acid.

    In plain wordsIn one person with Wolfram syndrome, blood sugar control improved after liraglutide plus another drug. The effect of liraglutide alone is unknown.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlycemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There was reduction in insulin requirements and improvement in glycemic control.
    1 context sentence
    Summary · context
    Treatment with liraglutide, a glucagon-like-peptide-1 receptor agonist, and tauroursodeoxycholic acid was started for the younger sibling, the proband.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.